Market Trends of Leptospirosis Industry
Penicillin Segment is Expected to Witness a Significant Growth Over the Forecast Period
The penicillin segment is expected to register a significant growth rate throughout the forecast period owing to factors such as the surge in research and development and an increase in the prevalence of leptospirosis. Also, the advantages of penicillin treatment over other treatments and growing commercial availability promote the segment's growth during the forecast period.
Research studies have highlighted penicillin's efficacy in controlling leptospirosis infection, which is expected to increase awareness about the disease and elevate the adoption of penicillin for controlling leptospirosis infection and boost segment growth. For instance, a research study published in Membrane in March 2022 stated that early penicillin therapy had been efficient and could significantly reduce the risk of patients suffering from multiple organ failure caused by a leptospirosis infection. Furthermore, intravenous (IV) penicillin is advised for severe leptospirosis. Further, a study published in the journal Process Biology in February 2023 mentioned a penicillin-binding protein obtained from the structural and biochemical characterization of Leptospira interrogans Lsa45, which can be used to control the infection of Leptospira interrogans. Thus, such advancing studies underline the efficacy of penicillin and reveal more target penicillin-binding proteins for more effective management of leptospirosis infection. These factors are expected to attract more market growth opportunities by tapping the vast patient base of leptospirosis and treating the disease using penicillin which will boost the segment's growth during the forecast period.
Furthermore, the growing number of leptospirosis infections will likely positively impact the segment's growth. For instance, in July 2022, the southern district of Lindi, Tanzania, identified 20 cases of leptospirosis, a bacterial infection that has killed three people. Also, per the data published by the Australian Government Department of Health and Aged Care in April 2022, over 14 cases were reported in the Top End of the Northern Territory, Australia, in 2021.
Thus, with the high prevalence of leptospirosis and the advancing research, the segment is estimated to project substantial growth over the analysis period.
North America is Expected to Dominate the Leptospirosis Market Over the Forecast Period
North America is expected to hold a significant share of the leptospirosis market due to the surge in leptospirosis epidemics and growing awareness of bacterial infections. Also, the presence of drug manufacturers is expected to boost regional market growth. The region also has significant pets associated with zoonotic diseases of leptospirosis. This will increase the demand for leptospirosis diagnosis and treatment and expand the market's growth in the region. For instance, per the data published by the American Pet Products Association 2023-2024, over 66% of the households representing 86.9 million homes owned a pet in 2023 in the United States. Further, as per the data published by Pet Keen in May 2023, Canada has the highest percentage of pet owners among all the developed countries, with cats in over 38% of households and dogs in over 35% of households. Research studies have highlighted the risk of contracting leptospirosis infection from pet animals. For instance, a study published in the journal PLOS in January 2022 underlined the high burden of the zoonotic disease of Leptospira in humans from exposure to pis-hunting dogs in Queensland, Australia.
The significant burden of leptospirosis is expected to create a high demand for leptospirosis drugs to manage the infection effectively, likely boosting the market growth in the region. For instance, the data provided by the Centers for Disease Control and Prevention in 2022 stated that the United States had experienced leptospirosis outbreaks owing to floods in Hawaii, Florida, and Puerto Rico in 2021.
Research articles have underlined the significant burden of leptospirosis in the region, which is expected to create more awareness about the infection and boost the demand for leptospirosis infections drugs. For instance, an article published in STATPEARLS in May 2022 stated that zoonoses constitute 61% of infectious diseases and 75% of emerging ones. According to the same source, Leptospira is the most common zoonotic disease worldwide, and most cases in the United States are observed in Hawaii in farmers, veterinarians, and surfers. Therefore, owing to the factors above, the growth of the leptospirosis market is anticipated to be boosted in the North American region.
Furthermore, the healthcare bodies in the region have increased their focus to elevate the R&D of leptospirosis drugs to control the disease effectively, and it is likely to boost the growth of the regional market by supporting pipeline antibiotics. For instance, in December 2021, the Centers for Disease Control and Prevention (CDC) launched two global networks. They awarded USD 22 million to nearly 30 organizations worldwide to combat antimicrobial resistance and infectious diseases. Leptospirosis was one of the contagious diseases being considered.
Therefore, with the high burden of leptospirosis and increasing research funding, the studied market is anticipated to grow in the North America Region.
